SUVENSuven Life Sciences Ltd.

    Suven Life Sciences Ltd: results and news

    Every Suven Life Sciences Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings.

    1 article · Biopharmaceutical drug discovery · Latest 5 Nov 2026

    SUVENSuven Life Sciences Ltd.

    Suven Life Sciences Q2 FY27 Results: Consolidated Net Loss ₹107 Crore on Total Income of ₹7.93 Crore

    Suven Life Sciences (NSE: SUVEN) reported a consolidated total income of ₹7.93 crore and a consolidated net loss of ₹106.94 crore for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. The standalone net loss for the quarter was ₹16.38 crore on the same total income of ₹7.93 crore.

    • Earnings
    • Biopharmaceutical drug discovery

    Blacklitt Research3 min read